Do Biosimilars Cost Less Than Reference Products?

Biosimilars are expected to cost anywhere from 10% to 40% less than their reference products.

One of the key reasons for this is because many original biologics are reaching the end of that exclusive patent period, and a number of manufacturers are working to bring biosimilars to market.